PD-1 and PD-L1 inhibitors in oesophago-gastric cancers

Area of Science:

• Oncology
• Immunotherapy

Background:

• Oesophago-gastric cancers (OGCs) are aggressive malignancies with limited treatment options.
• While advancements in chemotherapy and targeted therapy have improved survival, novel approaches are needed.
• Immune checkpoint inhibitors (ICIs) represent a promising new frontier in cancer treatment.

Purpose of the Study:

• To discuss the biological rationale for using ICIs in OGCs.
• To review current data on PD-1 and PD-L1 monoclonal antibodies in OGC treatment.
• To present ongoing clinical trials that may shape future OGC therapy.

Main Methods:

• Review of biological mechanisms underlying ICI efficacy in OGC.
• Analysis of clinical trial data for PD-1 and PD-L1 inhibitors in OGC.
• Summary of ongoing and future clinical trials involving ICIs in OGC.

Main Results:

• ICIs have demonstrated efficacy in refractory OGC settings, with regulatory approval in some regions.
• Evidence supports the potential benefit of modulating the anti-cancer immune response in OGC patients.
• Ongoing trials are investigating ICIs in early-stage disease and combination therapies.

Conclusions:

• ICIs are emerging as a significant treatment modality for oesophago-gastric cancers.
• Further research and clinical trials are crucial to optimize ICI use and combination strategies.
• ICIs hold the potential to transform the treatment landscape for OGC patients.